Trials / Not Yet Recruiting
Not Yet RecruitingNCT06594211
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
A Single-Arm, Open-Label Study of Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and efficacy of allogeneic anti-BCMA/GPRC5D bispecific chimeric antigen receptor natural killer (CAR-NK) cells (ACT-001) in patients with refractory or relapsed multiple myeloma (r/r MM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ACT-001 CAR-NK cell | Subjects were distributed into three dosage groups, each receiving a single dose of CAR-NK cells at levels of 1×10\^8, 3×10\^8, and 9×10\^8 cells, respectively. |
Timeline
- Start date
- 2024-10-09
- Primary completion
- 2028-10-09
- Completion
- 2028-10-09
- First posted
- 2024-09-19
- Last updated
- 2024-09-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06594211. Inclusion in this directory is not an endorsement.